期刊文献+

肾阳虚抑郁症模型大鼠的肝脏药物代谢酶活性变化研究 被引量:5

Change of hepatic drug metabolism enzymes in rat depression model with kidney-yang deficiency
原文传递
导出
摘要 采用鸡尾酒法(cocktail)探究糖皮质激素诱导的肾阳虚抑郁症状态大鼠体内6种CYP450亚型酶活性变化。连续21天肌注氢化可的松,建立肾阳虚抑郁症大鼠模型;分别选用甲苯磺丁脲、氯唑沙宗、茶碱、咪达唑仑、奥美拉唑和右美沙芬作为CYP2C6、CYP2E1、CYP1A2、CYP3A2、CYP2D1、CYP2D2探针底物。采用液质联用法(LC-MS/MS)测定空白组和模型组大鼠体内6种混合探针的血药浓度,计算药动学参数。与空白组相比,模型组大鼠体内茶碱、氯唑沙宗和甲苯磺丁脲的代谢显著加快(P<0.01),右美沙芬、奥美拉唑、咪达唑仑的代谢无显著差异。结果表明氢化可的松诱导的肾阳虚抑郁模型CYP2E1、CYP1A2和CYP2C6均被诱导。 This study was designed to explore the impact of depression on kidney-yang deficiency in rats. Rats were repeatedly injected with hydrocortisone for 21 days to establish the depression model with kidney- yang deficiency. Tolbutamide,chlorzoxazone,theophylline,midazolam,omeprazole and dextromethorphan were used as substrates of CYP2C6,CYP2E1,CYP1A2,CYP3A2,CYP2D1,and CYP2D2 to test the depression impact on drug metabolism. Plasma concentrations of six CYP450 were determined by LC-MS/MS and used as pharmacokinetic parameters. Consequently,metabolism of theophylline,chlorzoxazone and tolbutamide were accelerated significantly in the model relative to the control(P〈0.01),but dextromethorphan,omeprazole and midazolam did not exhibit a significant difference. The present study suggests that depression with kidney- yang deficiency had a strong induction of CYP2E1 and moderate induction of CYP1A2,CYP2C6 in the rat model.
出处 《药学学报》 CAS CSCD 北大核心 2017年第2期258-263,共6页 Acta Pharmaceutica Sinica
基金 国家自然科学基金资助项目(81573685) 江苏省中药资源产业化过程协同创新中心重点项目(ZDXM-2)
关键词 抑郁症 肾阳虚 鸡尾酒法 液质联用 细胞色素P450 depression kidney-yang deficiency cocktail probe drug LC-MS/MS cytochrome P450
  • 相关文献

参考文献3

二级参考文献27

  • 1Shams ME,Arneth B,Hiemke C,王小艳.CYP2D6的多态性与文拉法辛的临床效应[J].中国处方药,2006,5(10):26-26. 被引量:12
  • 2Krayenbuhl JC, Vozeb S, Kondo-OestreicherM, et al. Drug-drug interactions of new active substances : mibefradil example [J]. Eur J Clin Pharmacol, 1999, 55(8): 559-565.
  • 3Breimer DD, Schellens JH. A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans[J]. Trends Pharm Sci, 1990, 11 (6): 223-225.
  • 4U. S. FDA. Guidance for Industry - Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labelling[M]. 2006.
  • 5Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P -450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians[J]. J Pharmacol Exp Ther, 1994, 270(1): 414-423.
  • 6Robson RA, Miners JO, Matthews AP, et al. Characterization of theophylline metabolism by human liver microsomes: inhibition and immunochemical studies[J]. Biochem Pharmacol, 1988, 37(9): 1651- 1659.
  • 7Sarkar MA, Hunt C, Guzelian PS, et al. Characterization of human liver cytochromes P -450 involved in theophylline metabolism[J]. Drug Metab Disps, 1992, 20(1) : 31 -37.
  • 8Grygiel JJ, Wing LM, Farkas J, et al. Effects of allopurinol on theophylline metabolism and clearance[J]. Clin Pharmacol Ther, 1979, 26 (5) : 660 -667.
  • 9Lucas D, Ferrara R, Gonzalez E, et al. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans[J]. Pharmacogenetics. 1999, 9(3): 377-388.
  • 10Kharasch ED, Thummel KE, Mhyre J, et al. Single - dose disulfiram inhibition of chlorzoxazone metabolism : a clinical probe for P450 2E1[J]. Clin Pharmacol Ther, 1993, 53(6) : 643 -650.

共引文献14

同被引文献69

引证文献5

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部